Choose a language and wait for the translated text.
The setback for del-desiran, which Novartis acquired through its recent $12 billion acquisition of Avidity, increases pressure on CEO Vas Narasimhan and his M&A strategy to build up the firm's pipeline.
Novartis twin drug trial setbacks pile pressure on pipeline, CEO | PharmaVoice
